Intended Audience: Hematology/oncology teams, including physicians, NPs/PAs, pharmacists, nurses, and case managers, in the federal and public health settings
As CAR T-Cell approaches revolutionize treatment for hematologic malignancies, unique challenges arise in federal and public health settings. Join this live session to hear the latest evidence and expert insights on practical considerations for integrating CAR T-Cell Therapies into treatment for patients with hematologic malignancies.
This webinar is delivered in partnership with AMSUS, The Society of Federal Health Professionals.
I. Identifying potential candidates for CAR T-cell therapy across hematologic malignancies
II. Addressing barriers to access and supporting successful outcomes with CAR T-cell therapy
III. Case-based discussions in CAR T-cell treatment
Director of the Myeloma, Waldenström's, and Amyloidosis ProgramAssociate Professor of Internal MedicineDivision of Hematology/OncologyUT Southwestern Medical CenterDallas, TX
Medical Director, Immune Effector Cell Therapy ProgramDana Farber Cancer InstituteAssistant Professor of MedicineHarvard Medical SchoolBoston, MA
Senior Director of Specialty Pharmacy StrategyMaxor National Pharmacy Services, LLCIndianapolis, IN
Professor, Department of MedicineGeorge Washington University School of MedicineClinical Professor of Medicine, Uniformed Services UniversityAdjunct Professor of Medicine, Georgetown University Medical SchoolChief, Hematology and Medical OncologyChair, Institute for Clinical Research (ICR)Washington DC VA Medical CenterWashington, DC
Visiting ProfessorGeorge Washington UniversityFamily Nurse PractitionerWheeling Health RightWheeling, WV
Medical DirectorHumanaFort Lauderdale, FL
PharmacistNew York Presbyterian Hospital - Lower ManhattanNew York, NY
PRIME® designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0 hour of pharmacology).
This Application-based activity has been approved for 1.0 contact hour (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-21-192-L01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service ([email protected]).
PRIME® designates this activity for 1.0 contact hour.
The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers. Credits for this program are pre-approved.
Instructions to access CME/CE credit options will be provided at the end of the program.
*PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with commercial interests to disclose:
The following individuals have no relevant financial relationships with commercial interests to disclose:
All PRIME® staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.